Status
Conditions
Treatments
About
A Prospective, Multicenter, Randomized, Pivotal Study of the May Health System in Transvaginal Ablation of Ovarian Tissue under Ultrasound Guidance in Women with Infertility due to Polycystic Ovary Syndrome
Full description
The objective of the study is to provide evidence for the safety and effectiveness of the May Health System in transvaginal ablation of ovarian tissue under transvaginal ultrasound guidance to restore ovulation in women with infertility due to polycystic ovary syndrome (PCOS) who have not responded to first-line ovulation induction treatment or are contraindicated for or decline such treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥ 18 to ≤ 40 years
Infertility associated with oligo- or anovulation, AND EITHER:
2.1 Ultrasonographic evidence of PCOS (ovarian volume ≥ 10 mL and/or ovarian antral follicle count per ovary ≥ 20) OR
2.2 Evidence of hyperandrogenemia: either clinical (hirsutism defined as modified Ferriman-Gallwey (mFG) level ≥ 4-6 depending on ethnicity) or biochemical (raised serum concentration of androgens, testosterone ≥ 2.5 nmol/L, or FAI > 4)
At least one ovary with ovarian volume ≥ 10.0 mL and neither ovary > 23.0 mL
Ovarian accessibility: determined by ability to bring transvaginal ultrasound transducer into close proximity to at least one ovary. (Note: In the situation where only one ovary is appropriately sized according to the preceding criterion, then this requirement applies to the qualifying ovary.)
At least one patent fallopian tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years
Has not responded to first-line ovulation induction treatment or is contraindicated for, or declines, such treatment
Currently seeking immediate fertility
Willing to comply with Clinical Investigation Plan-specified follow-up evaluations
Ability to understand study requirements and has sufficient fluency in one of the approved written translations of the Patient Information and Informed consent form
Signed informed consent
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
195 participants in 2 patient groups
Loading...
Central trial contact
Christina Hawley, MPH; Bertha Torres
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal